Journal article

A role for XRCC2 gene polymorphisms in breast cancer risk and survival

Wei-Yu Lin, Nicola J Camp, Lisa A Cannon-Albright, Kristina Allen-Brady, Sabapathy Balasubramanian, Malcolm WR Reed, John L Hopper, Carmel Apicella, Graham G Giles, Melissa C Southey, Roger L Milne, Jose I Arias-Perez, Primitiva Menendez-Rodriguez, Javier Benitez, Magdalena Grundmann, Natalia Dubrowinskaja, Tjoung-Won Park-Simon, Thilo Doerk, Montserrat Garcia-Closas, Jonine Figueroa Show all

Journal of Medical Genetics | BMJ PUBLISHING GROUP | Published : 2011


BACKGROUND: The XRCC2 gene is a key mediator in the homologous recombination repair of DNA double strand breaks. It is hypothesised that inherited variants in the XRCC2 gene might also affect susceptibility to, and survival from, breast cancer. METHODS: The study genotyped 12 XRCC2 tagging single nucleotide polymorphisms (SNPs) in 1131 breast cancer cases and 1148 controls from the Sheffield Breast Cancer Study (SBCS), and examined their associations with breast cancer risk and survival by estimating ORs and HRs, and their corresponding 95% CIs. Positive findings were further investigated in 860 cases and 869 controls from the Utah Breast Cancer Study (UBCS) and jointly analysed together wit..

View full abstract


Awarded by Breast Cancer Campaign

Awarded by Susan G. Komen Breast Cancer Foundation

Awarded by Avon Foundation

Awarded by NCI

Awarded by National Cancer Institute, National Institutes of Health

Awarded by Fondo de Investigacion Santiario

Awarded by Cancer Research UK

Awarded by The Francis Crick Institute


Funding Acknowledgements

The SBCS study was funded by the Breast Cancer Campaign (grants 2000:146 and 2004 Nov 49), and Yorkshire Cancer Research core funding. The UBCS was supported by the Susan G. Komen Breast Cancer Foundation (BCTR0706911 to NJC) and the Avon Foundation (02-2009-080 to NJC). Data collection in Utah was made possible by the Utah Population Database (UPDB) and the Utah Cancer Registry (UCR). Partial support for all datasets within the UPDB was provided by the University of Utah Huntsman Cancer Institute (HCI) and the HCI Cancer Center Support grant, P30 CA42014 from the NCI. The UCR is funded by contract HHSN261201000026C from the NCI SEER program with additional support from the Utah State Department of Health and the University of Utah. The Australian Breast Cancer Family Study was supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (CFR) and principal investigators. The University of Melbourne (U01 CA69638) contributed data to this study. The content of this manuscript does not necessarily reflect the views or the policies of the National Cancer Institute or any of the collaborating centres in the CFR, nor does mention of trade names, commercial products or organisations imply endorsement by the US government or the CFR. JLH is a National Health and Medical Research Council Australia Fellow. MCS is a National Health and Medical Research Council Senior Research Fellow. JLH and MCS are both group leaders of the Victoria Breast Cancer Research Consortium. The CNIO-BCS work was partly funded by the Red Tematica de Investigacion Cooperativa en Cancer, the Asociacion Espanola Contra Cancer and grants from the Fondo de Investigacion Santiario (PI081583 to RLM and PI081120 to JB). SEARCH is funded by Cancer Research UK (C490/A10124) and the Cambridge NIHR Biomedical Research Centre. The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The USRT study was funded by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.